Abstracts

The Ring Comes Full Circle: Navigating the Complex Landscape of Biomedical Prevention Post-Phase III

Presentation: The biomedical prevention landscape enters a pivotal phase as dapivirine (DPV) vaginal ring progresses beyond Phase III clinical trials. This presentation explores: the role of open-label extension (OLE) studies in refining Phase III results, insights from recent PEPFAR-based data in Zimbabwe on real-world ring use, and the intricate balance required in shaping future target…

Challenging the Dogma of Event-Driven PrEP

Presentation: HIV is preventable with the use of daily oral PrEP or long-acting injectable PrEP for all populations regardless of sex or gender. Additionally, event-driven PrEP is an option for cisgender men who desire intermittent use of medications. The IPERGAY Trial provided an important answer, intermittent dosing of PrEP is an effective method to prevent…

Why Is Cabotegravir Rollout So Slow?

Presentation: Long-acting injectable cabotegravir as pre-exposure prophylaxis for HIV prevention (LAI CAB PrEP) has been FDA approved in the U.S. since December 2021. Approvals are in place or pending in many countries and regions globally, and it is being evaluated for programmatic implementation in a variety of contexts. Since FDA approval in the U.S., LAI…

Sex Differences in Atherosclerotic CVD Risks and Mechanisms: Insights From REPRIEVE

Presentation: The presentation highlights risks for atherosclerotic cardiovascular disease, particularly myocardial infarction, among ART-treated people with HIV, with attention to sex-differences in such risks. Sex-differences in the pathophysiologic mechanisms contributing to risks for myocardial infarction among people with HIV are also explored. Finally, data supporting sex-specific risk mechanisms among women with HIV are presented.

From Transcriptomics to Therapeutics: A Host Restriction Factor That Targets HIV Expression

Presentation: Advances in unbiased next-generation sequencing methods for characterizing all RNA transcripts in a sample have revolutionized scientific research in the past decade, leading to discoveries related to how variation in people impacts responses to disease outcomes, vaccination and therapeutics. Transcriptomics assays expression from every gene in an organism’s genome to reveal the global pattern…

From Structure to Therapeutics: CD4 Mimetics ‘Open’ Env and Sensitize HIV-1-Infected Cells to ADCC

Presentation: Combination antiretroviral therapy (cART) controls human immunodeficiency virus (HIV-1) replication and extends the longevity of persons living with HIV-1 (PLWH). Even with optimal cART, latent HIV-1 proviruses persist in long-lived reservoirs, from which virus rebounds within days to weeks of treatment interruption. Therefore, new approaches aimed at eliminating HIV-1 reservoirs are needed. Persistently infected…

From Mechanisms to Therapeutics: Eliminating HIV-Infected Cells by the CARD8 Inflammasome

Presentation: A successful curative strategy for HIV should aim at selective elimination of HIV-infected cells. The ‘shock-and-kill’ approach involves inducing viral gene expression to trigger immune clearance of infected cells. One of the main obstacles is the presence of immune escape variants in HIV reservoirs. Therefore, broadly reactive T cell and antibody responses are required…

From Mechanisms to Therapeutics: TACK Molecules Kill HIV-Infected Cells Through Inflammasome Activation

Presentation: The viral reservoir, consisting of both HIV-1–expressing and latently infected cells, necessitates life-long antiretroviral therapy (ART) to suppress HIV-1 replication in people living with HIV (PLWH). Current ART blocks viral replication and prevents spread to healthy cells. In doing this it maintains, but does not reduce, the HIV infected cell reservoir. A common approach…